More about Suven Pharmaceuticals Limited
Fundamentals for Suven Pharmaceuticals Limited
Regulatory Filings for Suven Pharmaceuticals Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Suven Pharmaceuticals Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
Revenue projections:
SUVENPHAR's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 56.269436 |
| debtToEquity | 1.945000 |
| earningsGrowth | 0.755000 |
| revenueGrowth | 0.397000 |
| grossMargins | 0.627760 |
| operatingMargins | 0.316950 |
| trailingEps | 10.900000 |
| forwardEps | 0.000000 |
Suven Pharmaceuticals Limited's forward PE is elevated, which could constrain price appreciation and lead to a correction. Investors should consider this parameter in conjunction with other fundamentals to fully assess whether the stock is priced fairly.
Suven Pharmaceuticals Limited's positive earnings and revenue growth suggest the company is on a path to business expansion. This upward trend signals strong financial health, indicating that Suven Pharmaceuticals Limited is well-positioned for sustained growth in both profits and revenue.
SUVENPHAR's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
Price projections:
SUVENPHAR's price currently reflects projections without revealing significant risks or opportunities. This status quo implies that investors may experience minimal fluctuations in the stock, leading to a cautious approach in trading decisions until future indicators emerge.
Recommendation changes over time:
Recent analysis shows a strong buy bias for SUVENPHAR, encouraging investors to view it as a solid investment option. The positive sentiment surrounding SUVENPHAR suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape